Last reviewed · How we verify

Bromfenac 0.09%

Bucci Laser Vision Institute · FDA-approved active Small molecule Quality 5/100

Bromfenac 0.09% is a Small molecule drug developed by Bucci Laser Vision Institute. It is currently FDA-approved. Also known as: Xibrom.

At a glance

Generic nameBromfenac 0.09%
Also known asXibrom
SponsorBucci Laser Vision Institute
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bromfenac 0.09%

What is Bromfenac 0.09%?

Bromfenac 0.09% is a Small molecule drug developed by Bucci Laser Vision Institute.

Who makes Bromfenac 0.09%?

Bromfenac 0.09% is developed and marketed by Bucci Laser Vision Institute (see full Bucci Laser Vision Institute pipeline at /company/bucci-laser-vision-institute).

Is Bromfenac 0.09% also known as anything else?

Bromfenac 0.09% is also known as Xibrom.

What development phase is Bromfenac 0.09% in?

Bromfenac 0.09% is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing